Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANX1502 Safety and PK Study in Healthy Volunteers
NCT05521269Phase 1Completed
- Sponsor
- Annexon Biosciences
- Start
- Jun 2022
- Primary completion
- Nov 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ANX1502 in cold agglutinin disease (CAD) (2 arms), sponsored by Annexon Biosciences. Primary endpoint: Number of Participants with Treatment Emergent Adverse Events. Started Jun 2022; status: completed.
02
Drugs
ANX1502
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT05521269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521269.